1,928 results on '"Bates, Susan"'
Search Results
352. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
353. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma
354. Abstract LB-244: Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors
355. Abstract LB-241: Genomic characterization of breast cancer cells resistant to the histone deacetylase inhibitor romidepsin
356. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat
357. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo
358. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
359. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
360. Literature Listing
361. Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran’s health data.
362. Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.
363. The rate of tumor growth during treatment accurately predicts the FDA gold standard of overall survival [OS] in a broad range of malignancies.
364. A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC).
365. Future heat waves and surface ozone
366. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
367. Revisiting the role of ABC transporters in multidrug-resistant cancer
368. Internal climate variability and projected future regional steric and dynamic sea level rise
369. Abstract LB-B26: Novel eIF4A inhibitors target both cellular and microenvironment components in pancreatic ductal adenocarcinoma
370. Clinical Trials in Pancreatic Cancer: A Long Slog
371. Literature Listing
372. INTRINSIC DRUG RESISTANCE IN PRIMARY AND METASTATIC RENAL CELL CARCINOMA
373. Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833
374. Pots of colour.
375. Step back in time.
376. Hormones and Oncogenes in Human Breast Cancer
377. Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2
378. Biological and Environmental Research Exascale Requirements Review
379. Life: Its Many Dimensions
380. Atlantic and Pacific tropics connected by mutually interactive decadal-timescale processes
381. Stitch and relax.
382. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2
383. Faculty Opinions recommendation of Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.
384. Faculty Opinions recommendation of The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
385. Faculty Opinions recommendation of Brain accumulation of ponatinib and its active metabolite, N-Desmethyl ponatinib, is limited by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
386. Refining Immunotherapy Approvals
387. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy
388. Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels
389. Abstract 4040: Short-term romidepsin treatment combined with clotrimazole or bifonazole leads to decreased mitochondrial hexokinase 2 and apoptosis in cancer cells
390. A tribute to Eugene Garfield: A bibliography of publications relating to patents
391. Metabolic symbiosis in cancer and its therapeutic implication
392. Base Pairs to Populations
393. Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
394. Pancreatic Cancer: Challenge and Inspiration
395. Current challenges in the management of breast cancer brain metastases
396. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials
397. DNA Topoisomerase Targeting Drugs
398. Too Many Journals
399. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
400. Mutational analysis of ABCG2: role of the GXXXG motif
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.